Side-by-side · Research reference
EpitalonvsPancragen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticAUTO-DRAFTED8/37 cited
BAnimal-StrongHUMAN-REVIEWED23/39 cited
Epitalon
Pineal bioregulator · Telomerase activator
SQ or IM · Abdomen · Daily for 10–20 days
01Mechanism of Action
Parameter
Epitalon
Pancragen
Primary target
Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Pathway
Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Downstream effect
Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Feedback intact?
—
Yes — preserves physiological glucose-insulin response
Origin
Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Antibody development
—
—
02Dosage Protocols
Parameter
Epitalon
Pancragen
Standard dose
5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003
Anecdotal community protocol. Russian clinical literature uses similar cycling.
—
Lower / starter dose
2.5 mg / day
—
Evidence basis
In-vitro telomerase + Russian clinical trialsKhavinson 2003
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Duration
10–20 day cycles, 1–2× per year
—
Reconstitution
Bacteriostatic water
—
Timing
Pre-sleep preferred (pineal alignment)
—
Half-life
Hours (estimated)
—
Primate dose (rhesus macaque)
—
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
Diabetes model
—
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
04Side Effects & Safety
Parameter
Epitalon
Pancragen
Injection site reaction
Mild irritation
—
Sleep architecture
Improved subjective sleep quality (anecdotal)
—
Cancer risk
Theoretical via telomerase activation in pre-malignant cells
—
Long-term safety
Limited Western RCT data
—
Pregnancy / OB
Avoid
—
Antibody formation
Not reported
—
Reported adverse events
—
None documented in primate studies
Human safety data
—
No published human trials; clinical use limited to Russian gerontology protocols
Absolute Contraindications
Epitalon
- ·Pregnancy / breastfeeding
- ·Active malignancy or pre-malignant state
Pancragen
—Relative Contraindications
Epitalon
- ·Family history of cancer
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
05Administration Protocol
Parameter
Epitalon
Pancragen
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
2. Injection site
SQ — abdomen preferred. Rotate sites.
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
3. Timing
Pre-sleep preferred to align with pineal axis.
No specific timing constraints documented. Administered once daily in primate protocols.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
5. Needle
29–31G, 4–8 mm insulin syringe.
—